Last checked at 
(Alliance News) - Life sciences firm ValiRx PLC said Thursday the US granted patent protection for the use of its VAL201 metastatic cancer treatment.
The US Patent & Trademark Office granted patent 10,400,008 to the lead therapeutic compound at ValiRx, VAL201.
The patent protects use of the VAL201 peptide in the progress reduction and treatment of metastatic cancer, including prostate cancer.
"Since all primary cancers will metastasise and can spread anywhere around the body at some point, this US patent grant, covering one of our largest commercial markets, represents a key addition to our patent coverage and protection for this indication," Chief Executive Officer Satu Vainikka said.
"I look forward to the further development of the VAL201 compound and the validation of its potential anti-cancer impact", Vainikka added.
Shares in ValiRx were 0.1% lower at 0.13 pence in London on Thursday.
By Ahren Lester; ahrenlester@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
